<DOC>
	<DOCNO>NCT01967381</DOCNO>
	<brief_summary>The research propose application determine initial efficacy , safety tolerability novel drug combination , oxazepam ( Serax® ) naltrexone ( Revia® ) , pharmacotherapy methamphetamine ( Desoxyn® ) dependence . A rigorous , inpatient human laboratory study conduct . The propose study innovative important provide impetus conduct double blind , placebo-controlled trial demonstrate efficacy combine oxazepam naltrexone manage methamphetamine dependence .</brief_summary>
	<brief_title>Targeting GABA Opioid Systems Pharmacotherapy Methamphetamine Abuse</brief_title>
	<detailed_description />
	<mesh_term>Oxazepam</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Lifetime methamphetamine use Abnormal screening outcome ( e.g. , ECG , blood chemistry result ) study physician deem clinically significant Current past history substance abuse dependence deem study physician interfere study completion History serious physical disease , current physical disease , impair cardiovascular functioning , chronic obstructive pulmonary disease , history seizure current past history serious psychiatric disorder opinion study physician would interfere study participation exclude participation Females currently use effective birth control Contraindications methamphetamine ( Desoxyn® ) , oxazepam ( Serax® ) naltrexone ( Revia® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>